ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality

Heart

Volumn 100, Issue 21, 2014, Pages 1715-1721

  Hughes, Maria F ^a,b,d,e   Appelbaum, Sebastian ^a,b   Havulinna, Aki S ^c   Jagodzinski, Annika ^a,b   Zeller, Tanja ^a,b   Kee, Frank ^d   Blankenberg, Stefan ^a,b   Salomaa, Veikko ^c  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ADULT; AGE DISTRIBUTION; AGED; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FEMALE; FINLAND; FOLLOW UP; FORECASTING; HEALTH SURVEY; HEART FAILURE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SURVIVAL RATE; TRENDS;

ADULT; AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; FEMALE; FINLAND; FOLLOW-UP STUDIES; FORECASTING; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 84922055928     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305968     Document Type: Article

References (30)

1. Murray CL, Lopez AD. Measuring the global burden of disease. New Engl J Med 2013;369:448-57.
2. Zeller T, Tunstall-Pedoe H, Saarela O, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation the MORGAM biomarker project Scottish cohort. Eur Heart J 2014;35:171-81.
3. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts (the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarkers project. Circulation 2010;121:2388-97.
4. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress. The framingham heart study. Circulation 2012;126:1596-604.
5. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-26.
6. Sanada S, Hakuno D, Higgins LJ, et al. IL33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Investig 2007;117:1538-49.
7. Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survial after experiemental myocardial infarction through ST2 signalling. Circ Heart Fail 2009;2:684-91.
8. Turnquist HR, Zhao Z, Rosborough BR, et al. IL-33 expands suppressive CD11b+ Gr-1 (int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011;187:4598-610.
9. Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009;2:311-19.
10. Ky B, French B, McCloskey K, et al. High sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-87.
11. Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44.
12. Kohli P, Bonaca MP, Kakkar R, et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012;58:257-66.
13. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
14. Weir R A P, Millar AM, Murphy G E J, et al. Serum soluble ST2 a potential novel mediator in left ventricular and infarct remodelling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-50.
15. Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population based cohort: The Dallas heart study. Clin Chem 2013;59:536-46.
16. Millar AM, Purves D, McConnachie A, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?. Plos One 2013;7:e47830.
17. Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012;58:1673-81.
18. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504-18.
19. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish hospital discharge register and causes of death register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005;12:132-37.
20. Mähönen M, Jula A, Harald K, et al. The validity of heart failure diagnoses obtained from administrative registers. Eur J Prev Cardiol 2013;20:254-9.
21. Deiplinger B, Januzzi JL, Steinmair M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma; the Presage ST2 assay. Clin Chim Acta 2009;409:33-40.
22. van Buuren S, Groothuis-Oudshoorn K Mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software 45, 2011.
23. Inker LA, Schmid CH, Toghiouart H, et al. Estimating glomeruler filtration rate from serum creatinine and cystatin C. New Engl J Med 2012;367:20-9.
24. Hsieh FY, Lavori PW. Sample size calculations for the Cox proportional hazards regression model with non-binary covariates. Control Clin Trials 2000;21:552-60.
25. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44.
26. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of the net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
27. Felker GM, Fiuzat M, Thompson V, et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 2013;6:1172-9.
28. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscl Throm Vas 2011;31:2080-89.
29. Dieplinger B, Egger M, Poelz W, et al. Long-term stability of soluble ST2 in frozen plasma samples. Clin Biochem 2010;43:1169-70.
30. Funke-Kaiser A, Havulinna AS, Zeller T, et al. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med 2014;46:155-62.